A pre-clinical COVID-19 vaccine trial sparked much speculation in a Canadian biotech stock Friday. Here’s some small stocks making big moves on Friday, March 27, 2020 (as of 4 pm EST):
Vaxil Bio Ltd. (TSXV:VXL), a Canadian biotech stock, powered 30% higher to $0.195 on Friday after announcing that it has a non-GMP vaccine material in hand and has begun to execute its pre-clinical program to test the efficacy of the Company’s COVID-19 vaccine candidate. Vaxil Bio added that it has applied for an additional patent in connection with COVID-19.
As well, shares of Tinkerine Studios Ltd. (TSXV:TTD) gained 38% to $0.145 as the provider of 3D printing products said it has received initial orders for its Face Shield. As of official production and launch, the Company received interest of 4500+ Face Shield inquires over 24 hours.
K92 Mining Inc. (TSXV:KNT), meanwhile, reported that its Fiscal 2019 revenue surged 91% to US$101.7 million, while posting a record yearly profit of US$32.5 million, or US$0.16 per share. The Company also recorded AISC of US$680 per gold ounce for the year, exceeding its upgraded guidance of US$720-760/oz gold. K92 Mining stock moved up 3% to $3.07 following the announcement.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Vaxil Bio Ltd. (TSXV:VXL), a Canadian biotech stock, powered 30% higher to $0.195 on Friday after announcing that it has a non-GMP vaccine material in hand and has begun to execute its pre-clinical program to test the efficacy of the Company’s COVID-19 vaccine candidate. Vaxil Bio added that it has applied for an additional patent in connection with COVID-19.
, on Friday.){kind=link}